Saturday, 21 October 2017

AstraZeneca’s Global Medicines Development group set to expand in Bangalore

11 September 2017 | News

This latest expansion forms part of a broader plan in the Global Medicines Development (GMD) group to transform exciting new science and the company’s rich pipeline into more life-changing medicines for patients

Source: Pixabay

Source: Pixabay

AstraZeneca’s Global Medicines Development group is building up its hub in Bangalore and recruiting physicians, scientists and regulatory experts as part of plans to support global management of established medicines for its growing portfolio which cover treatments across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases.

The company currently employs around 30 experienced physicians and scientists in Bangalore who are engaged in pharmacovigilance activities which support the monitoring of its medicines on the market around the world, and ensure continued safe use for patients. The intent is to expand that team, and to also add regulatory roles and other physician roles to support global management of established medicines. New offices are being set up for the expanding team in Bangalore.

Recruitment is now underway and AstraZeneca is working with experienced recruitment partners to support the search for individuals with the right competence, and in the ambition of completing recruitment by end 2018.

This latest expansion forms part of a broader plan in the Global Medicines Development (GMD) group to transform exciting new science and the company’s rich pipeline into more life-changing medicines for patients.

Veena Rajan, Head of Patient Safety, Bangalore within the Global Regulatory, Patient Safety and Quality Assurance group, said: “We are already fortunate to have very talented people working with us in Bangalore, and we are looking to grow that team to build on the excellent work they are delivering in support of our late-stage and mature product portfolio.  As we all know, the Bangalore region, including Mumbai & Chennai, is an expanding area for the pharma industry, including several medical and biopharmaceutical companies, and there are many people here who are furthering their medical education. We aim to benefit from being part of this growing infrastructure and expand on the activities we are already successfully delivering from this location.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is India becoming dependent on imports for key drug intermediates?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls